Celiac Disease - Pipeline Review, 2019

Celiac Disease is a type of autoimmune disease which generally occurs due to ingestion of gluten that is present in wheat, rye, and barley. Celiac disease can lead to severe damage to the small intestine and with other serious complications. The disease is also called as gluten-sensitive enteropathy, celiac sprue, and non-tropical sprue. Nausea and vomiting, abdominal pain, bloating and gas, weight loss, and fatigue are some of the symptoms of celiac disease. According to the Celiac Disease Foundation, globally, an estimated 1 out of 100 people get affected by celiac disease each year.

At the present situation, there is no drug available to cure celiac disease, however, ingestion of gluten-free food and medicines are widely recommended over the world in order to prevent the occurrence of celiac disease. 

Pharmaceutical companies and other drug manufacturers are prominently focusing on studying and developing new treatment options for the celiac disease. For instance; Nexvax2, which is being studied by ImmusanT, Inc, is currently in phase-2 clinical trials to check its efficacy and tolerability for the treatment of celiac disease.

At present around 75% of the pipeline candidates for celiac disease are in the phase-1 and phase-2 stage. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Celiac Disease – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Celiac Disease. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Celiac Disease.

The report on ‘Celiac Disease – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Celiac Disease


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Celiac Disease


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary